14th edition

Format
HYBRID

December 2nd & 3rd, 2025

IN-PERSON | STRASBOURG

December 8th ,2025

ONLINE MEETINGS

14th edition

Format
HYBRID

December 2nd & 3rd, 2025

IN-PERSON | STRASBOURG

December 8th ,2025

ONLINE MEETINGS

Stand E2/D8 – 6

2017 Edition

DYNACURE

fr

Dynacure is a biotechnology company founded in 2016 that is developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a rare debilitating disease affecting children and young adults. Dynacure’s Dyn101 is an antisense oligonucleotide developed in collaboration with IONIS Pharma (USA).

Scroll to Top
  • No products in the cart.